NEW YORK (GenomeWeb) – C2N Diagnostics today announced the expansion of a partnership with Washington University School of Medicine in St. Louis to commercialize a clinical blood test for the detection of Alzheimer's disease at its earliest stages, as well as mild cognitive impairment.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A company says it can generate likenesses of people based on their genetic profiles.

IBM's Watson is learning how to treat leukemia as a fellow at the MD Anderson Cancer Center, according to the Washington Post.

In Cell this week: dynamics of protein profusion and localization, melanoma classification schemes, and more.

In PNAS this week: ancestry and admixture in Brazilians, characterization of novel double-stranded RNA mycovirus, and more.